McKesson Corporation is transforming from a traditional distributor to a tech-enabled healthcare services leader, focusing on high-margin specialty and digital solutions. Recent acquisitions (PRISM Vision, Core Ventures) and organizational restructuring position MCK for sustained growth in oncology, multispecialty, and technology-enabled segments. Q1 FY26 results showed strong revenue growth, r...
McKesson Corporation is rated 'Buy' due to its transformation into a higher-growth, higher-margin healthcare services platform focused on Oncology & Multispecialty and Prescription Technology Solutions. MCK's upgraded long-term adjusted EPS growth target of 13%-16%, aggressive capital returns, and strategic realignment support a bullish outlook and potential for significant stock price apprecia...
McKesson Corporation (NYSE:MCK ) Analyst/Investor Day September 23, 2025 9:30 AM EDT Company Participants Brian Tyler - CEO & Director Britt Vitalone - Executive VP & CFO Kirk Kaminsky - President of The US Pharmaceutical & Specialty Solutions Business Joan Eliasek - President Jason Hammonds Kevin Kettler Conference Call Participants Lisa Gill - JPMorgan Chase & Co, Research Division George Hil...
McKesson on Tuesday raised its profit forecast, as the U.S. drug distributor aims to focus on high-margin businesses such as cancer medicines to boost growth.
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will host its 2025 Investor Day today, beginning at 9:30 AM ET. During the event, executive leadership will discuss the company's multi-year strategic priorities, growth strategies, and long-term business outlook. The Investor Day event will showcase how McKesson continues to accelerate long-term growth and deliver sustained value...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.